Factors Influencing Adherence to Tuberculosis Treatment in the Ketu North District of the Volta Region, Ghana
Tuberculosis Research and Treatment · 30.03.2021 · 2021 · 1-6
DOI: 10.1155/2021/6685039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tuberculosis Research and Treatment, erschienen am 30.03.2021. Verfasst von Eyram Dogah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Disease Control Unit, Ketu North Municipal Health Directorate, Ghana Health Service, Dzodze, Volta Region, Ghana. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Annually, ten million cases of tuberculosis (TB) and about 1.8 million mortalities are recorded. Adherence to TB treatment not only reduces death outcomes but prevents prolonged sickness, transmission to others, and the development of multidrug-resistant TB. This study is aimed at determining the rate of treatment adherence, knowledge of TB infection, and the possible factors influencing adherence to TB treatment in the Ketu North District in the Volta Region of Ghana. A cross-sectional study design was employed. A semistructured questionnaire was used to obtain data from respondents. Adherence to TB treatment and knowledge level about TB infection were assessed. A Chi-square test analysis was used to determine the variables that were associated with treatment adherence. Logistic regression analysis was used to determine potential factors that contribute to treatment adherence. A total of 125 TB registrants were enrolled in the study. The majority (102 (81.6%)) adhered to the TB treatment regimen. However, the level of knowledge about night sweat being a symptom of TB infection was relatively low (78 (62.4%)). Logistic regression analysis revealed that the male gender was about three times more likely ( OR = 2.978 , 95 % CI = 1.173 ‐ 7.561 ; p = 0.022 ) to be associated with adherence to TB treatment. However, food availability ( OR = 2.208 , 95% CI (0.848-5.753); p = 0.10 ) and household size ( OR = 0.538 , 95% CI (0.195-1.483); p = 0.23 ) were not significantly associated with treatment adherence. In this study, adherence to TB treatment and the knowledge level of TB infection were high. However, the knowledge level of night sweat being a symptom of TB infection was relatively low. Being a male was significantly associated with treatment adherence. An intensified health education on the symptoms of TB infection is therefore recommended.
Autor:innen und Institutionen
- Disease Control Unit, Ketu North Municipal Health Directorate, Ghana Health Service, Dzodze, Volta Region, Ghana.
- Department of Health Policy, Planning and Management, School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana.
- Hohoe Municipal Health Directorate, Ghana Health Service, Hohoe, Volta Region, Ghana.
- Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Health and Allied Sciences, Ho, Ghana.
ORCID-Profile: Eyram Dogah, Da-Ama Mawulom Kuatewo, Godsway Edem Kpene, Florence Shine Edziah
Zitieren
APA
Dogah, E., Aviisah, M., Kuatewo, D. M., Kpene, G. E., Lokpo, S. Y., & Edziah, F. S. (2021). Factors Influencing Adherence to Tuberculosis Treatment in the Ketu North District of the Volta Region, Ghana. Tuberculosis Research and Treatment, 2021, 1-6. https://doi.org/10.1155/2021/6685039
Vancouver
Dogah E, Aviisah M, Kuatewo DM, Kpene GE, Lokpo SY, Edziah FS. Factors Influencing Adherence to Tuberculosis Treatment in the Ketu North District of the Volta Region, Ghana. Tuberculosis Research and Treatment. 2021;2021:1-6. doi:10.1155/2021/6685039
BibTeX
@article{Dogah2021,
author = {Dogah, Eyram and Aviisah, Mark and Kuatewo, Da-Ama Mawulom and Kpene, Godsway Edem and Lokpo, Sylvester Yao and Edziah, Florence Shine},
title = {Factors Influencing Adherence to Tuberculosis Treatment in the Ketu North District of the Volta Region, Ghana},
journal = {Tuberculosis Research and Treatment},
year = {2021},
volume = {2021},
pages = {1--6},
doi = {10.1155/2021/6685039}
}
EUVIMED